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A B S T R A C T
Objective: To evaluate the efﬁcacy of vagus nerve stimulation (VNS) in pediatric patients with medically
refractory epilepsy.
Method: We reviewed the medical records of 252 consecutive patients who underwent VNS
implantation at a single center over a 5-year period. Patients with complete 6- and 12-month
follow-up data were included. Analysis was also done across various subgroups including gender, age at
implantation, seizure type, abnormal MRI ﬁndings pre-implantation, number of medications at baseline,
history of SE, and duration of epilepsy.
Results: Complete follow-up data were available for 69 patients. Median seizure reduction for these
patients was 50% (Q1: 0%; Q3: 73%) at 6 months and 40% (Q1: 25%; Q3: 75%) at 12 months. When
stratiﬁed by baseline seizure frequency, there was a signiﬁcant reduction from baseline of 61% at 6
months and 69% at 12 months for patients in the high-baseline frequency group. There were no
signiﬁcant reductions at month 6 or 12 months for the lower-baseline frequency group. Adverse events
were reported in 40.6% (28 out of 69 patients). Six patients had the VNS removed for reasons including
lack of efﬁcacy and side effects and were excluded from the study group.
Conclusion: VNS provides signiﬁcant seizure reduction, in particular in pediatric patients with a higher
baseline seizure frequency.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Vagus nerve stimulation (VNS) is an established adjunctive
therapy for medically refractory epilepsy.1,2 The therapy was
approved in 1997 by the US Food and Drug Administration for use
in adolescents and adults.3 Combined analysis of these trials
concluded that VNS therapy allowed 1/3 of treated patients to
achieve a greater than 50% reduction in seizure frequency, a
reduction which may continue even with long term use.4While the
VNS is established for use in adults,5–8 its potential value in the
treatment of drug-resistant epilepsy in a pediatric population has* Corresponding author at: Harvard Medical School, Division of Epilepsy and
Clinical Neurophysiology, Fegan 9, Children’s Hospital Boston, 300 Longwood
Avenue, Boston, MA 02115, United States. Tel.: +1 617 355 2443;
fax: +1 617 730 0463.
E-mail address: tobias.loddenkemper@childrens.harvard.edu
(T. Loddenkemper).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.10.002not been conclusively established. Recently a small prospective
study has been published suggesting that VNS may be effective in
some children and adolescents, though not in others.9,12,26 To date,
few investigators have explored the efﬁcacy and safety of VNS for
refractory epilepsy in large pediatric populations over time.10–13
In this retrospective study, we aimed to expand the reported
experience of VNS use in a pediatric population, with data from a
single center. In addition, we also attempted to determine whether
any speciﬁc clinical characteristics were associated with more
favorable outcomes after VNS placement.
2. Methods
2.1. Patient selection
Prior to chart-review, institutional review board approval was
obtained for this study. We reviewed the medical records of allvier Ltd. All rights reserved.
Fig. 1. Consort diagram. Only patients with complete data at baseline, month 6, and
month 12 were included in statistical analysis. Sixty-nine patients were included.
*Search using ICD-9 codes used returned some patients who did not undergo VNS
implantations, but who underwent similar procedures for treatments in
otolaryngology.
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2011 at Boston Children’s Hospital. Patients were identiﬁed using
the International Classiﬁcation of Diseases, Ninth Revision codes
02.93, 89.15, 86.94, 86.95, 86.96, and 86.98. All medical records
and reports of MRI ﬁndings were reviewed. Seizure outcome and
VNS side effects were derived from the patient records and
evaluated along with brain MRI ﬁndings, seizure type and
localization, and previous seizure treatments.
2.2. VNS implantation
Implantation was performed by the same neurosurgeon
following standard procedures (J.R.M.). Stimulation parameters
were initially set at 0.25–0.5 mA current, 20–30 Hz frequency,
250–500 ms pulse width, 30 s on time and 5–10 min off time; the
magnet current was generally set 0.25 mA higher with a
stimulation duration of 60 s. Parameter adjustments were made
at subsequent follow-ups by the patient’s neurologist according to
accepted adult guidelines.14Fig. 2. Percentage change of seizures from baseline to 6 months. Patients in the low base
50%; 75% quartiles, 50%) at 6 months (p = 0.94). Patients in the high baseline group (G
quartile, 50%) at 6 months (p < 0.001).2.3. Follow-ups
Seizure frequency data was acquired at baseline (within 180
days prior to VNS implantation), at 6 month (2 month window)
and at 12 month (3 month window) follow-up visits. Patients were
required to have complete seizure data at all three of these time
points to be included in the analysis.
Given the wide range of seizure frequencies at baseline,
subjects were categorized by seizure frequency into a high-
frequency group (those with a baseline frequency above the group
median) and a low-frequency group (those with a baseline
frequency below this median).
2.4. Statistical analysis
The primary outcome measure was the percentage change from
baseline seizure frequency at the 6- and 12-month follow-ups.
Differences in seizure percentage change were assessed using a
Wilcoxon signed-rank test.
Subgroup comparisons were undertaken to assess if the median
percentage change from baseline to 12 month follow-up was
signiﬁcantly different between the various groups stratiﬁed by
demographic characteristics as speciﬁed in Table 3. P values <0.05
were considered statistically signiﬁcant. All statistical analyses
were performed using SAS, 9.3 (SAS, Cary, NC).
3. Results
3.1. Patient inclusion (Fig. 1)
Sixty-nine patients had complete data both at baseline and the
two follow-up periods and formed the study group. Patients who
had the VNS removed before 12 months were excluded from the
analysis, though outcomes for this group are reported separately
(Figs. 2 and 3.).
3.2. Population demographics
The median seizure frequency at baseline was 45 seizures/
month (Q1: 10 seizures/month; Q3: 150 seizures/month). Patients
were grouped according to the baseline median with Group 1 (lowline group (Group 1) experienced a median seizure reduction of 25% (25% quartile,
roup 2) experienced a median seizure reduction of 61% (25% quartile, 93%; 75%
Fig. 3. Percentage change of seizures from baseline to 12 months. Patients in the low baseline group (Group1) experienced a median seizure reduction of 0% (25% quartile,
50%; 75% quartiles, 100%) at 12 months (p = 0.39). Patients in the high baseline group (Group 2) experienced a median seizure reduction of 69% (25% quartile, 96%; 75%
quartile, 30%) at 12 months (p < 0.001).
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Group 2 (high baseline group, n = 35) experiencing >45 seizures/
month. Demographic data for the population are outlined in Tables
1 and 2.
3.3. Results at six months (Table 3)
Thirty-seven (53.6%) out of 69 patients exhibited seizure
reductions of 50% (achieved responder status) at six months.
Seventeen patients (24.6%) achieved a 75% or greater reduction
from baseline seizure frequency. Four patients (5.8%) achieved
seizure freedom. Of the remaining 32 patients with less than 50%
reduction (classiﬁed as non-responders), 17 (24.6%) experienced
an increased number of seizures compared to baseline.
Compared to baseline, the overall population experienced a
median reduction of 50% (Q1: 0%; Q3: 73%) at six months
(p = 0.005). The high baseline group (>45 seizures/month at
baseline) exhibited a median reduction from baseline of 61% (Q1:
50%; Q3: 93%) at 6 month follow-up (p < 0.001). The median
seizure frequency at 6 months was signiﬁcantly lower than at
baseline. The low baseline seizure frequency group (n = 35)
experienced a 25% median reduction in seizure frequency from
baseline (Q1: 50%; Q3: 50%). The difference in median seizure
frequency from baseline to month 12 was not statistically
signiﬁcant (p = 0.94).
3.4. Results at 12 months (Table 3)
At 12 months, 28 (40.6%) patients experienced seizure
reductions 50%. Seventeen (24.6%) patients experienced a
>75% reduction. Four patients (5.8%) were seizure free at 12
months. The remaining 41 (59.4%) patients had a less than 50%
reduction in seizure frequency. Of these 41 patients, 20 had an
exacerbation in seizure frequency compared to baseline.
At the 12 month follow-up, the overall population had a
median reduction of 40% (Q1: 25%; Q3: 75%) from baseline
frequency (p = 0.058). Analyzing the population with respect to
high and low baseline groups, the high baseline group achieved
signiﬁcant reductions at 12 months follow-up, exhibiting a
seizure reduction of 69% (Q1: 30%; Q3: 96%) from baseline
(p < 0.001). The low baseline group did not show an overallreduction from baseline seizure frequency (median 0%, Q1: 50%;
Q3: 50%) (p = 0.39).
3.5. Subgroup analysis
Among patients with the selected baseline characteristics we
did not identify signiﬁcant differences in outcome at 12 months
follow-up (Table 3). Results suggested that in the low baseline
group of patients, those younger than 10 years old at time of VNS
implantation (n = 20) experienced a trend toward greater seizure
reduction compared to those older than 10 years (n = 15) (p = 0.06).
While numbers of patients with syndromes and epilepsy-related
comorbidities were limited, outcomes in these groups are
presented in supplemental Table 1.
3.6. VNS settings at 0, 6 and 12 months (supplemental Table 1)
Sixty-eight patients had an increase in current at 6 months and
61 had a further increase at 12 months. There was no signiﬁcant
difference in VNS settings including current, on-time or off-time
between the low and high-frequency baseline groups at 6- and 12-
month follow-ups (supplemental Table 2).
3.7. Discontinuation of VNS therapy
Six patients discontinued VNS treatment within the 12 month
follow-up period. Reasons for discontinuation included infection
requiring explantation of the device (n = 3), excessive nausea
resulting in the VNS being turned off (n = 1), skin breakdown over
the device leading to explantation (n = 1), and perceived lack of
efﬁcacy (n = 1).
3.8. Adverse effects of VNS therapy
Twenty-eight patients complained of adverse events that did
not require discontinuation of therapy. The most frequently
reported side-effect was seizure exacerbation of 50% from
baseline (n = 14). Other side effects included voice changes
(n = 8), coughing (n = 6), hoarseness (n = 4), throat tickle/para-
esthesias (n = 3), sleep apnea (n = 1), and nausea and vomiting
(n = 1).
Table 2
Demographic data for study groups at baseline.
Characteristics All subjects
(N = 69)
GP1: low
baseline
45 seizuresa
(N = 35)
GP2: high
baseline
>45 seizuresa
(N = 34)
Gender, No (%)
Female 29 (42%) 17 (49%) 12 (35%)
Male 40 (58%) 18 (51%) 22 (65%)
Age at VNS
N N = 69 N = 35 N = 34
Median 10 years old 9 years old 11 years old
(Q1, Q3) (5,14) (5,15) (5,14)
Number of medications
<3 28 (41%) 16 (46%) 12 (35%)
3 41 (59%) 19 (54%) 22 (65%)
Seizures at baseline
N N = 69 N = 35 N = 34
Median 45 10 150
(Q1, Q3) (10, 150) (6, 30) (90, 300)
Semiological characteristics, number (%)
Simple 1(1%) 1(1%) 0
Complex 25 (36%) 13 (37%) 12 (35%)
Generalized 43 (62%) 21 (60%) 22 (65%)
Duration of epilepsy (years)
N N = 69 N = 35 N = 34
Median 8.3 8.1 8.5
(Q1, Q3) (4.6,11.3) (4.5,11.1) (4.6,12.1)
Epilepsy syndromes/comorbidities
Nb N = 14 N = 10 N = 4
Lennox Gastaut syndrome N = 8 N = 2 N = 8
Cerebral Palsy N = 5 N = 1 N = 4
Rett’s syndrome N = 2 N = 2 N = 0
Autism N = 11 N = 8 N = 3
a Demographic data of the high and low baseline groups were similar to that of
the overall population.
b A total of 14 patients were diagnosed. One patient had both Lennox Gastaut
Syndrome and Cerebral Palsy.
Table 1
Demographic data for the overall population at baseline.
Number of patients 69
Number of girls 29
Mean age (SD, range) Mean 18.56yrs
(SD = 6.81, Range 4-36yrs)
Past history of Status Epilepticus (SE) 16
Patients who developed SE after implanta 10
Age of seizure onset 28.63 months
(SD = 34.32, Range
birth-132 months)
Age at VNS implantation 11.07 yrs (SD = 5.31,
Range 2-25yrs)
Seizure etiology
Symptomatic 25
Idiopathic 36
Cryptogenic 8
Semiological characteristics
Generalized 32.
Complex partial 6
Complex Partial with secondary generalization 28
Simple partial 1
Simple Partial with secondary
generalization
2
EEG characteristics
EEG available 63
Generalized and Focal 29
Multifocal 16
Generalized 7
Frontal 5
Temporal 5
Parietal 1
Lateralization
Left 6
Right 8
No Lateralization 49
Imaging
MRI Available 61
Normal MRI 21
Abnormal MRI 40
MRI ﬁndings
Volume loss (unspeciﬁed) 13
Gliosis 11
Status post resection 8
Agenesis/Dysgenesis 8
Cortical Dysplasia 6
Encephalomalacia/Trauma 6
Cystic Lesions 4
Hydrocephalus 3
Polymicrogyria 2
Hemiatrophy 1
Tumor 1
MRI lesion lateralization
Left 7
Right 5
Both 26
Unspeciﬁed 2
AEDsa
Mean AEDs, baseline 2.73 (Range 1–5)
Mean AEDs at 6 months 2.58 (Range 1–5)
Mean AEDs at 12 months 2.72 (Range 1–6)
Resective surgerya
Surgery pre implant 7
Surgery post implant 1
a Data such as development of SE after implantation, number of AED’s and each
follow-up, and additional epilepsy surgery were collected at subsequent follow-
ups. Abbreviations: yrs., years; s/p, status post.
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4.1. Summary
VNS may be effective in patients with high baseline seizure
frequency. However, vagus nerve stimulation may lack long-term
efﬁcacy in pediatric patients with lower baseline seizure frequen-
cies.4.2. Seizure reduction at 6 months
Our study population experienced seizure reduction at the 6
month follow-up. Similar results were reported in a retrospective
study of 125 patients indicating 51% seizure reduction at 6
months.11 Findings are also consistent with another retrospective
study with 46 children and adolescents.13
4.3. Seizure reduction at 12 months
Overall 40.6% patients continued to experience seizure reduc-
tion 50% after 12 months, and this was most prominent in
patients with high baseline seizure frequency. Seizure frequency
decrease in the low baseline seizure frequency group was not
signiﬁcant after 12 months. Another retrospective study noted that
31/69 pediatric patients had no worthwhile improvement in
seizure frequency at a mean follow-up time of 3.9 years.12
Additionally, 41 children and adolescents who received VNS
therapy for a mean 2.6 years reported treatment failure in about
40%.15 In a report of 96 pediatric patients treated for a mean of 2.7
years, 55% failed to respond to therapy.10 A randomized controlled
pediatric trial with 41 children and adolescents demonstrated
similar ﬁndings, with the majority of patients (74%) failing to
achieve signiﬁcant seizure reduction after 39 weeks.9 Furthermore,
an international survey study indicated limited efﬁcacy in 197
pediatric patients at one-year follow-up following VNS implanta-
tion.16 However, while VNS may cause limited seizure reduction, it
may nonetheless limit the severity of seizures. VNS in pediatric
epilepsy lowered hospital admissions, emergency room visits, and
events of status epilepticus and improved quality of life.17 Our data
now allow us to differentiate and interpret these results further
and identify baseline seizure frequency, using a cut off of 45
Table 3
Change in seizure frequency across subgroups in high and low baseline groups.
Total population (n = 69) Low baseline group (n = 35) High baseline group (n = 34)
N Median (Q1, Q3) P N Median (Q1, Q3) P N Median (Q1, Q3) P
Duration of Epilepsy 8.3 34 40% 18 13% 16 58%
(10%, 72%) (100%, 50%) (14%, 91%)
>8.3 35 40% 0.8 17 25% 0.44 18 81% 0.29
(33%, 92%) (67%, 40%) (38%, 97%)
Abnormal EEG ﬁndings Absent 25 20% 14 18% 11 54%
(50%, 60%) (150%, 50%) (0%, 96%)
Present 38 41% 0.26 19 17% 0.66 31 73% 0.47
(89%, 0%) (110%, 50%) (13%, 96%)
No. of medications <3 27 30% 0.11 16 0% 12 58%
(36%, 60%) (125%, 41%) (15%, 73%)
3 51 45% 19 10% 0.46 22 90% 0.19
(10%, 92%) (67%, 58%) (38%, 97%)
Prev. Episodes of No 51 50% 25 0% 27 72%
S.E. (25%, 91%) (100%, 50%) (38%, 96%)
Yes 16 34% 0.65 10 13% 0.61 6 55% 0.82
(77%, 66%) (36%, 45%) (30%, 96%)
Gender Female 29 38% 17 33% 12 70%
(36%, 73%) (150%, 43%) (39%, 93%)
Males 40 43% 0.22 18 21% 0.2 22 66% 0.99
(0%, 83%) (25%, 50%) (20%, 97%)
Age at VNS <10yrs 35 43% 20 32% 15 60%
(0%, 72%) (5%, 50%) (8%, 92%)
10 yrs 34 38% 0.72 15 36% 0.06 19 89% 0.54
(36%, 91%) (150%, 0%) (38%, 96%)
Age at VNS <12yrs 28 44% 12 43% 16 91%
(43%, 93%) (168%, 13%) (37%, 96%)
12 yrs 41 40% 0.72 23 17% 0.16 18 58% 0.24
(0%, 67%) (33%, 50%) (8%, 73%)
Seizure typea Focal 25 50% 13 10% 12 72%
(0%, 92%) (67%, 67%) (33%, 96%)
Generalized 43 40% 0.5 21 0% 0.55 22 69% 0.86
(25%, 73%) (50%, 43%) (20%, 92%)
Lateralization Unilateral 12 59%
of lesionb (18%, 84%)
Bilateral 28 18 0.31
(50%, 89%)
a Note: Only 1 subject had a seizure type of simplex was excluded for comparison among groups due to small number of subjects in this category. Abbreviations: yrs., years.
b Note: Sample sizes of these subgroups were too small to divide further into high and low baseline groups. Seizure outcomes at 12 months were compared across multiple
subgroups organized by baseline characteristics to determine which groups are most amenable to treatment. Although there were no signiﬁcant differences in seizure
outcome across these subgroups, patients in the low baseline group who were younger than 10 years of age experienced moderately better outcomes (p = 0.06).
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long-term response.
4.4. Efﬁcacy of VNS according to seizure frequency
Patients in our series with initial higher seizure burdens at
baseline responded more consistently to VNS. Similar ﬁndings
were noted in a retrospective study with 50 adult patients.18
Although seizure frequency may be a surrogate for epilepsy
subtype in some patients, we did not observe signiﬁcant
differences in our analyses by epilepsy syndrome.
4.5. Comparison of VNS to alternative therapies
Outcomes of VNS in pediatric patients may be comparable to
alternative treatment modalities for patients with refractory
epilepsy. Treatment with two medications in patients with
refractory epilepsy carries a 3% chance of seizure remission.19 In
children using the modiﬁed Atkins diet, 55% of patients had a
favorable response (>50% seizure reduction).20 In a randomized
controlled trial investigating ketogenic and medium chaintriglyceride diets, 17.8% of patients on the ketogenic diet and
22.2% on medium chain triglyceride diets had a favorable
response.21 Trials of anterior nucleus of thalamus stimulation
for refractory epilepsy demonstrated that 54% of patients had a
favorable response at 2 years.22 In a study evaluating trigeminal
nerve stimulation, thirty-eight percent of patients had a >50%
response.23 The present ﬁnding of 40.6% of patients having >50%
seizure reductions suggests that VNS is comparable to these other
treatments in the setting of refractory epilepsy.
4.6. Subgroup analyses
None of the baseline characteristics examined was associated
with differences in VNS outcomes. In the low baseline seizure
frequency group, younger patients showed moderately better
outcomes. Other pediatric studies have similarly failed to identify
differences in outcome based seizure type,12,15,24–26 MRI abnor-
mality,25 pre-implantation number of medications,27 and duration
of epilepsy.12,15,27,28 The responder rate of LGS patients in this
series was similar to those reported in other studies and did not
differ signiﬁcantly from the group as a whole.26,29,30
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To date, several studies have evaluated the efﬁcacy of VNS in
children under 12 years.10–13,15,25–28,30–34 Few have demonstrated
that younger age at implantation lead to better outcomes.13,25,34
Similar to the previously mentioned retrospective study of 46
patients,13 trends related to age at implantation in our study only
approached signiﬁcance at 12 months. A study with 135 patients
demonstrated that the pre-adolescent patients (0–12 years) had
better clinical outcomes than older patients, with the youngest
children (<6 years) experiencing superior outcomes.34 A study in
43 patients <12 years of age reported that 51% experienced seizure
reductions of >50%, and this is comparable to results in older
children and adults.26
4.8. Challenges
Findings need to be interpreted in the setting of data acquisition
and are subject to selection and information bias. The accuracy of
seizure reporting depended primarily on patient and/or caregiver-
reported information. There may be greater potential for seizure
reduction in patients with higher seizure frequencies. Additionally,
higher seizure frequency may make accurate seizure counts less
accurate, but we believe that we might have missed more seizures
at baseline than at follow up. While epilepsy subtype may have
been a factor in seizure frequency, numbers of patients with
epilepsy syndromes were too small in both groups to investigate
this claim.
4.9. Conclusion
VNS has limited efﬁcacy in pediatric epilepsy patients and in
our series some patients even had seizure worsening. However, in
selected patients with frequent seizures at baseline, VNS provides
meaningful seizure reduction. Further data, either through larger
comparative effectiveness or randomized controlled trials is
needed to guide patient selection in the very young. A multi-
center study may also be useful to determine if the same trends
exist at other centers and if there are any correlations between
these trends and various VNS stimulation parameters.
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